Photo from Jarushka Naidoo/X
Apr 11, 2024, 13:50
New blood test predicts clinical benefit to IO AND identifies which patient will develop toxicity by Jarushka Naidoo – LUNGevity Foundation
LUNGevity Foundation shared on X/Twitter:
“50% patients develop side effects from immunotx. New blood test predicts clinical benefit to IO AND identifies which patient will develop toxicity and require proactive monitoring. Important question esp for PD-L1>50% Great presentation by Jarushka Naidoo. AACR24″
Source: LUNGevity Foundation/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 11:26
Mar 29, 2025, 11:03
Mar 29, 2025, 10:55
Mar 29, 2025, 10:45
Mar 29, 2025, 10:11